Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Policy / Regulatory

China’s 2022 Western Medicine Trade Analysis: Growth and Challenges

Fineline Cube Feb 20, 2023

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...

Company Drug

CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...

Company Deals Medical Device

Chunlizhengda to Acquire Majority Stake in Surgimaster for Medical Power Tools

Fineline Cube Feb 20, 2023

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a...

Company Deals

Duoning Biotech Secures Global Rights to Junzhen’s Cell Counter Products

Fineline Cube Feb 20, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm...

Company Deals

Sansure Biotech Partners with Hunan Normal University for Research and Talent Development

Fineline Cube Feb 18, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company Deals

Amcor Acquires Shanghai-Based MDK to Expand Asia-Pacific Footprint

Fineline Cube Feb 18, 2023

Switzerland-based packaging firm Amcor (NYSE: AMCR) has unveiled the signing of a deal to acquire...

Company Drug

CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Feb 17, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...

Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Company Deals Digital

By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion

Fineline Cube Feb 17, 2023

China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug...

Company Deals

Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion

Fineline Cube Feb 17, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Deals Medical Device

Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion

Fineline Cube Feb 17, 2023

Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...

Company Drug

NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis

Fineline Cube Feb 17, 2023

The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...

Company

Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines

Fineline Cube Feb 17, 2023

US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...

Company Deals Digital R&D

WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services

Fineline Cube Feb 16, 2023

China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...

Company

Eppendorf to Start Construction on New Shanghai Production Site

Fineline Cube Feb 16, 2023

Germany-based life sciences service provider Eppendorf is set to begin work on a new production...

Company Deals

InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement

Fineline Cube Feb 16, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...

Company Drug

AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan

Fineline Cube Feb 16, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...

Posts pagination

1 … 553 554 555 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.